APR 1 9 2002

Dkt. 2799/58994/JPW/NML

#

THE UNITED STATES PATENT AND TRADEMARK OFFIC

Applicants: Elsa Goulmy

RECEIVERMoner: Jehanne Souaya

Serial No.: 09/269,250 APR 24 2002 Art Unit: 1655

TECH CENTER 1600/2900

Filed

: May 21, 1999

For

: METHOD FOR TYPING PF MINOR HISTOCOMPATIBILITY ANTIGEN

HA-1

1185 Avenue of the Americas New York, New York 10036 April 17, 2002

Assistant Commissioner for Patents Washington, D.C. 20231

Box: Sequence

Sir:

# COMMUNICATION IN RESPONSE TO MARCH 21, 2002 NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

This Communication is submitted in response to the March 21, 2002 Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures issued by the United States Patent and Trademark Office in connection with the above-identified application. A copy of the Notice To Comply is attached hereto as **Exhibit A**. The Notice provides a period of one month for filing a response. Therefore, a response to this March 21, 2002 Notice is due April 21, 2002. Accordingly, this Communication is being timely filed.

Applicants: Elsa Goulmy Serial No.:09/269,250 Filed: May 21, 1999

Page 2

The Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures indicates that a copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report.

In response, applicants submit as **Exhibit B** hereto a substitute paper copy of the "Sequence Listing". In addition, applicants submit herewith a substitute computer readable form (CRF) copy of the "Sequence Listing." Further, applicants submit herewith a Statement in accordance with 37 C.F.R. §1.821(f) as **Exhibit C**, certifying that the computer readable form containing the nucleic acid and/or amino acid sequences which was submitted contains the same information as the paper copy of the "Sequence Listing" which was submitted and contains no new matter.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invite the Examiner to telephone him at the number provided below.

Applicants: Elsa Goulmy Serial No.:09/269,250 Filed: May 21, 1999

Page 3

No fee is deemed necessary in connection with the filing of this Communication. If any other fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

hereby certify that correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

rt D. Katz

Registration No. 30,141

Robert D. Katz

Registration No. 30,141 Attorney for Applicants Cooper & Dunham LLP 1185 Avenue of the Americas New York, New York 10036

(212) 278-0400



### UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trad rk Office

MAR 2 6 2002

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NA	FIRST NAMED APPLICANT			
09/269,250	5/21/99		Goulmy		2799/58994/RDK/JML	
Robert D. Katz Cooper & Dunham 1185 Avenue of the	Americas	3/21/2002				
New York, NY 1003		4/21/2002	1	EXAMIN	ER	ı
APD 4 0 coop	- m = 1	6/21/2002		Jehanne Souaya		
£	B 4 mai	7/21/2002		ART UNIT	PAPER NUMBER	
STANGE TO A STANGE OF THE STAN	5 mo: 8	8/21/2002		1634	22	
The state of the s	5 mos: 8/21/2 6 mos: 9/21/2		DATE MAILED:		RECEIVI	
		Sept.			APR 24 200	12

Please find below a communication from the EXAMINER in charge of this application CENTER 1600/2900 Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). A computer readable form (CRF) of the sequence listing was submitted. However, the CRF could not be processed by the Scientific and Technical Information Center (STIC) for the reason(s) set forth on the attached CRF Diskette Problem Report.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached CRF Diskette Problem Report with the reply.

Any inquiry concernithis communication or earlier communications from the examiner should be directed to examiner Jehanne Souaya whose telephone number is (703)308-6565. The examiner can normally be reached Monday-Thursday from 7:30 AM to 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703) 308-1152. The fax phone number for this Group is (703) 305-3014.

Any inquiry of a general nature should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Jehanne Souaya
Patent examiner
March 18, 2002

RECEIVED

pplication No.: <u>09/269, 25</u>0

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/ORTAMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this	application does not
comply with the requirements for such a disclosure as set forth in 37 C.F following reason(s):	F. P. 1.821 NT 1825 FOR the
Tollowing reason(s).	IECH CENTEN 1000/2000

	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 111 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
<b>]</b>	A. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	<ol> <li>The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).</li> </ol>
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Арр	olicant Must Provide:
7	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
<u></u>	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
or	questions regarding compliance to these requirements, please contact:
	Rules Interpretation, call (703) 308-4216
	CRF Submission Help, call (703) 308-4212 entIn Software Program Support
	Technical Assistance703-287-0200
	To Purchase Patentin Software 703 206 2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



#### **CRF** Problem Report

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF): Application Serial Number: RECEIVED

ECH CENTER 1600/2000 Filing Date: Date Processed by STIC: STIC Contact: Mark Spencer, 703-308-4212 Nature of Problem: The CRF (was): (circle one) Damaged or Unreadable (for Unreadable, see attached) Blank (no files on CRF) (see attached) Empty file (filename present, but no bytes in file) (see attached) Virus-infected. Virus name: The STIC will not process the CRF. Not saved in ASCII text Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should only be the Sequence Listing. Did not contain a Sequence Listing. (see attached sample) Other:

™CHNOLOGY ✓STEMS BRANCH

## PLEASE USE THE CHECKER VERSION 3.1 PROGRAM TO REDUCE ERRORS. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<a href="http://www.uspto.gov/ebc/efs/downloads/documents.htm">http://www.uspto.gov/ebc/efs/downloads/documents.htm</a>, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
- 3. Hand Carry directly to:

U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202

U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

 Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002